Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Optinose (NASDAQ: OPTN), often associated with the ticker OPRx, is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose, and throat (ENT) and allergy specialists. Their primary product is XHANCE® (fluticasone propionate) nasal spray, which utilizes their patented Exhalation Delivery System (EDS™) designed to deliver medication high and deep into the nasal passages for conditions like chronic rhinosinusitis with or without nasal polyps. The company aims to improve patient outcomes by addressing unmet medical needs in these therapeutic areas. In May 2024, Collegium Pharmaceutical announced a definitive agreement to acquire Optinose.
Serves as the main corporate office, housing executive leadership, administrative functions, commercial operations, and overseeing research and development strategy.
The headquarters is located in a modern office park, offering standard corporate facilities designed for collaboration and operational efficiency. Specific architectural highlights are not widely publicized.
As a pharmaceutical company, the culture likely emphasizes innovation, patient-centricity, scientific integrity, and collaboration between departments. Employees may experience a focused environment driven by clinical development and commercialization goals.
The Yardley headquarters is central to Optinose's U.S. operations, strategic planning, and stakeholder communication, particularly as they manage the commercialization of XHANCE and navigate clinical development programs.
Optinose's primary commercial focus is currently the United States market with its product XHANCE. While its technology has European origins (Norway), its operational and commercial activities are heavily centered in the U.S. Future global presence expansion would likely involve partnerships for ex-U.S. commercialization or development.
1020 Stony Hill Road, Suite 300
Yardley
Pennsylvania
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, OptimizeRx' leadership includes:
OptimizeRx has been backed by several prominent investors over the years, including:
The most significant executive-related news in the last 12 months is the pending acquisition of Optinose by Collegium Pharmaceutical. Post-acquisition, changes in the executive team are anticipated, with CEO Ramy Mahmoud expected to join Collegium's Board. No other major C-suite hires or departures were prominently announced in the 12 months prior to the acquisition news.
Discover the tools OptimizeRx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Optinose likely utilizes common corporate email formats. Based on industry standards and patterns observed for similar companies, the primary formats would involve combinations of first name, last name, and initials.
[first].[last]@optinose.com or [first_initial][last]@optinose.com
Format
jane.doe@optinose.com
Example
80%
Success rate
GlobeNewswire (via Optinose IR) • May 9, 2024
Optinose, Inc. (NASDAQ:OPTN) today announced that it has entered into a definitive agreement to be acquired by Collegium Pharmaceutical, Inc. (NASDAQ:COLL). Under the terms of the agreement, Collegium will acquire Optinose for an upfront cash payment and contingent value rights. The transaction is expected to close late in the second quarter or early in the third quarter of 2024....more
GlobeNewswire (via Optinose IR) • March 26, 2024
Optinose announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for XHANCE (fluticasone propionate) nasal spray as a treatment for adults with chronic sinusitis. The Prescription Drug User Fee Act (PDUFA) goal date for the FDA to complete its review is December 16, 2024....more
GlobeNewswire (via Optinose IR) • February 27, 2024
Optinose reported financial results for the fourth quarter and full year ended December 31, 2023. The company highlighted XHANCE net revenue growth and provided updates on its clinical programs and commercial activities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including OptimizeRx, are just a search away.